Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 3 art units • 4 examiners • 0 of 5 (0%) have an AI response strategy ready
BETTA PHARMACEUTICALS CO., LTD currently has 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 4 actions are being handled by 4 distinct examiners, meaning each examiner is responsible for exactly one case. These cases are spread across 3 distinct art units. Christopher Evan Redwood is listed as the busiest examiner with 1 busiest examiner pending action. Because each of the 4 distinct examiners has only 1 pending action, the designation of busiest examiner is shared across the entire group.
The presence of 3 distinct art units for only 4 pending office actions indicates that the Biotechnology & Pharmaceuticals filings are not concentrated in a single niche but are instead being reviewed by a variety of specialized groups within the USPTO. For the practitioner, this means that the 4 pending office actions are likely to receive specialized feedback tailored to different aspects of the company's technology. Since there are 4 distinct examiners, the legal strategy must be flexible enough to address four different individual styles. The fact that Christopher Evan Redwood and the other examiners each handle 1 busiest examiner pending action suggests a balanced prosecution landscape. To manage these 4 pending office actions effectively, the practitioner should monitor the 3 distinct art units for any overlapping prior art that could affect the Biotechnology & Pharmaceuticals portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| §112 only | 1 (20%) |
| Double-patenting + other | 3 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HADDAD, MAHER M | 2 | 50.6% | +53.8% |
| REDWOOD, CHRISTOPHER EVAN | 1 | 0.0% | +0.0% |
| MAHLUM, JONATHAN DAVIS | 1 | 50.0% | +23.3% |
| BORALSKY, LUKE ALAN | 1 | 66.7% | +44.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18847130 | MUTANT IDH1 AND IDH2 INHIBITOR AND APPLICATION THEREOF | REDWOOD, CHRISTOPHER EVAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18572432 | APPLICATION OF COMPOUND IN PREPARATION OF DRUG FOR TREATING MYELOFIBROSIS AND RELATED SYMPTOMS/SIGNS THEREOF, AND USE OF COMPOUND | BORALSKY, LUKE ALAN | 9d |
| 18706666 | BICYCLIC COMPOUND AND APPLICATION THEREOF | MAHLUM, JONATHAN DAVIS | — |
| 18692312 | BISPECIFIC ANTIBODY AND APPLICATION THEREOF | HADDAD, MAHER M | — |
| 18294516 | ANTI-PD-L1 NANOBODY AND USE THEREOF | HADDAD, MAHER M | — |
| Art Unit | Apps |
|---|---|
| 1641 | 2 |
| 1625 | 1 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18847130 | MUTANT IDH1 AND IDH2 INHIBITOR AND APPLICATION THEREOF | REDWOOD, CHRISTOPHER EVAN | — | §103Other | Non-Final OA | — | Pending | Sep 13, 2024 |
| 18706666 | BICYCLIC COMPOUND AND APPLICATION THEREOF | MAHLUM, JONATHAN DAVIS | 1625 | §102§112DP | Non-Final OA | — | Pending | May 01, 2024 |
| 18692312 | BISPECIFIC ANTIBODY AND APPLICATION THEREOF | HADDAD, MAHER M | 1641 | §112 | Non-Final OA | — | Pending | Mar 14, 2024 |
| 18294516 | ANTI-PD-L1 NANOBODY AND USE THEREOF | HADDAD, MAHER M | 1641 | §112DP | Final Rejection | — | Pending | Feb 01, 2024 |
| 18572432 | APPLICATION OF COMPOUND IN PREPARATION OF DRUG FOR TREATING MYELOFIBROSIS AND RELATED SYMPTOMS/SIGNS THEREOF, AND USE OF COMPOUND | BORALSKY, LUKE ALAN | 1624 | §103§112DP | Non-Final OA | 9d | Pending | Dec 20, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBETTA PHARMACEUTICALS CO., LTD has 5 pending office actions as of October 2026, spread across 3 art units and 4 examiners.
Maher M Haddad has the most, with 2 of BETTA PHARMACEUTICALS CO., LTD's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
